NeoGenomics

NeoGenomics announced a strategic focus on NGS and MRD tests as central growth drivers, with NGS revenue up 26% in the first half of 2026 and the portfolio now generating annualized revenue of over $250 million. Management expects NGS and MRD to increase their share of revenue from about one-third to more than half and to achieve margins in the mid-60% range. Key drivers include Medicare reimbursement for RaDaR ST in immunotherapy indications, improved revenue cycle management, and the refinancing of most convertible bonds in 2028. NeoGenomics is focusing on outpatient oncology, expanding the PanTracer product portfolio and operational efficiencies including a switch to NovaSeq X, aiming to reach positive free cash flow in 2026. » More on de.investing.com

NeoGenomics has received expanded Medicare coverage from the MolDX program of the U.S. agency CMS for its RaDaR ST test to detect molecular residual disease (MRD). The coverage now includes monitoring response to immune checkpoint inhibitors in patients with advanced solid tumors, marking the third Medicare indication for the test. Two additional reimbursement applications for RaDaR ST are still pending; the test supports post-surgical risk assessment, surveillance monitoring, and measurement of therapy response. » More on de.investing.com

NeoGenomics’ shares climbed to a 52-week high of $16.93 and are currently trading at $16.98, supported by a one‑year performance of about 167.48% and high volatility (beta 1.73). In the second quarter the company beat expectations with adjusted earnings of $0.05 per share (consensus $0.03) and revenue of $202 million, raised its full-year guidance and EBITDA, and received a $19.00 price target and “Buy” rating from Needham. InvestingPro values the stock as overvalued; additionally, Alicia Olivo, executive VP and general counsel, announced her resignation effective September 21, 2026. » More on de.investing.com